Health-related quality of life (HRQOL) among patients with Generalised Anxiety Disorder: evaluation conducted alongside an escitalopram relapse prevention trial

Health-related quality of life (HRQOL) among patients with Generalised Anxiety Disorder: evaluation conducted alongside an escitalopram relapse prevention trial

2007 Curr. Med. Res. Opin

Allgulander, C. | Jorgensen, T. | Wade, A. | Francois, C. | Despiegel, N. | Auquier, P. | Toumi, M. | Volume: 23, Issue: 10, Pages: 2543-2549, Affect, analysis, Anti-Anxiety Agents, Anxiety, Anxiety Disorders, Citalopram, Double-Blind Method, drug therapy, Female, Humans, Male, methods, physiopathology, Placebos, prevention & control, Quality of Life, Questionnaires, therapeutic use, Treatment Outcome,

BACKGROUND: Improving health-related quality of life (HRQoL) should be a treatment goal for patients with Generalised Anxiety Disorder (GAD). OBJECTIVES: To assess the impact of treatment with escitalopram on HRQoL as well as the effect of relapse on HRQoL and work productivity. METHODS: This study was conducted alongside a double-blind, placebo-controlled, relapse prevention multinational clinical trial. Relapse was defined as a Hamilton Anxiety Scale (HAMA) >or= 15. Treatment responders (HAMA

https://www.doi.org/10.1185/030079907X226087